focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Share News (AGL)

Share Price Information for Angle (AGL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 23.25
Bid: 23.00
Ask: 23.50
Change: 2.00 (9.41%)
Spread: 0.50 (2.174%)
Open: 20.75
High: 23.50
Low: 20.50
Prev. Close: 21.25
AGL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Shield closer to Canada approval; Angle plans raise

Thu, 14th Jul 2022 21:44

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

----------

Shield Therapeutics PLC - Newcastle, England-based commercial-stage pharmaceutical company - Its Accrufer-Feraccru iron deficiency treatment gets new drug submission approval from Health Canada. "Health Canada are expected to complete their regulatory review in mid-2023 and a successful outcome will allow KYE to market Accrufer in Canada. Shield will be responsible for all manufacturing and supply to the Canadian market," it adds. Company nets GBP250,000 milestone payment for approval and eligible for an additional GBP600,000 in milestone payments upon the achievement of specified calendar net sales targets.

----------

PureTech Health PLC - Boston, Massachusetts-based clinical-stage biotherapeutics firm - Subsidiary Akili Interactive Labs Inc's Systemic Lupus Erythematosus treatment, AKL-T01, sees significant improvement in motor speed and executive functions in study. The study results were published in the medical journal Lupus, it notes. Akili Chief Medical Officer Anil Jina says: "The results of this study in patients with SLE are consistent with the cognitive improvements seen in other studies after using our digital therapeutic. We are excited to see this continued validation of our technology platform as we advance our pipeline to deliver clinically meaningful cognitive and quality-of-life improvements across patient populations."

----------

Audioboom Group PLC - London-based podcast producer - Renews partnerships with "key" podcasts including Dark History, Murder Mystery & Makeup and No Such Thing As A Fish. Also plans to expand "creator network" through new commercial agreements with two podcasts, Fair Game with Leah Remini and The Roman Atwood Podcast.

----------

Angle PLC - Surrey, England-based medical diagnostics company - Proposes placing equal to 10% of existing issued share capital through placing and subscription. Says net proceeds will be used to help its commercialisation plans for its Parsortix system. Number of shares to be placed, and the price, will be determined after the bookbuild closes. Hopes to raise about GBP20 million.

----------

Greatland Gold PLC - mine developer and explorer in Western Australia - Renegotiates obligations for consideration due under the original 2016 acquisition of the Havieron project. Initial deal sees payment of AUD25,000 cash and issue of 65.5 million shares and further 145.5 million shares conditional upon Greatland's ownership interest in Havieron reducing to 25% on a decision to mine at Havieron. Says Five Diggers, who is receiving the shares, now agrees to take 4.5% reduction in shares, now totalling 139.0 million and equals GBP14.5 million saving, and agrees to 2-year restriction on dealing.

Shaun Day, managing director of Greatland Gold, says: "This is an excellent outcome, simultaneously removing the uncertainty of this long-standing share issue, reducing shareholder dilution by decreasing the number of shares being issued and introduces a two-year restriction on dealing with the shares."

----------

MGC Pharmaceuticals Ltd - Perth, Australia-based medicinal cannabis company - Sees "successful results" of clinical study into the influence of its ArtemiC Support on patients with post-acute Covid Syndrome, also known as long Covid. "ArtemiC Support, has demonstrated the ability of the supplement to improve the symptoms of long Covid," it says.

----------

Panther Metals PLC - mineral exploration in Canada - "Delighted" with "stunning" drilling results from Burtville East gold project and Eight Foot Well prospect in Western Australia. Notes result finds 1 metre at 79.90 grammes per tonne gold from 27 metres and 1 metre at 478.00 grammes per tonne from 28 metres, both coming from hole BVE006. Chief Executive Darren Hazelwood says the results reinforce the case for further exploration at Burtville East.

----------

Premier African Minerals Ltd - British Virgin Islands-based minerals and metals project developer - Sees "impressive" results from Zulu lithium and tantalum project. "The work to date has provided the level of confidence we needed internally to support the pilot plant concept as recently announced. In fact, what we are now understanding about the Zulu deposit is entirely complementary to the use of sensor-based ore sorting and in time is likely to result in a most efficient and effective process," Chief Executive George Roach says.

----------

Capital Ltd - mining services company - Wholly-owned subsidiary MSALABS expands partnership with Chrysos Corp. Tie in will see MSALABS deploy 21 Chrysos PhotonAssay units across its project by 2025. Notes revenue guidance for MSALABS in 2022 remains about USD30 million. Following the rollout of the further 15 units across 2023 and 2024, in conjunction with the expansion of the existing geochemistry business, MSALABS anticipates generating revenues in excess of USD80 million per annum.

----------

By Paul McGowan; paulmcgowan@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
14 Aug 2020 12:41

Angle's Parsortix Able To Predict Patients' Response To Treatment

Angle's Parsortix Able To Predict Patients' Response To Treatment

Read more
20 Jul 2020 20:03

IN BRIEF: Angle Notes Study Showing "Key Capabilities" Of Parsortix

IN BRIEF: Angle Notes Study Showing "Key Capabilities" Of Parsortix

Read more
20 Jul 2020 10:16

Angle's 'Parsortix' advantageous in breast cancer in new research

(Sharecast News) - Angle announced on Monday that the University of Southern California (USC) has published peer-reviewed results of new work undertaken in metastatic breast cancer (MBC), highlighting advantages of a 'Parsortix' liquid biopsy, compared to standard-of-care tissue biopsy.

Read more
25 Jun 2020 12:22

Angle Progresses On Parsortix And De Novo Clearance From US Regulator

Angle Progresses On Parsortix And De Novo Clearance From US Regulator

Read more
18 Jun 2020 16:05

UK Earnings, Trading Statements Calendar - Next 7 Days

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more
10 Jun 2020 16:41

IN BRIEF: Haydale Graphene Appoints Former AIM Market COO To Board

IN BRIEF: Haydale Graphene Appoints Former AIM Market COO To Board

Read more
12 May 2020 18:54

Angle's Parsortix Could Be Used To Pick MET Inhibitor Trial Subjects

Angle's Parsortix Could Be Used To Pick MET Inhibitor Trial Subjects

Read more
12 May 2020 08:58

Angle upbeat on recent research using 'Parsortix'

(Sharecast News) - Liquid biopsy company Angle announced on Tuesday that the liquid biopsy analysis unit at the Health Research Institute of Santiago in Spain has published results of new work undertaken in head and neck cancer and non small cell lung cancer, on the potential utility of a liquid biopsy-based strategy to assess MET alterations on circulating tumour cells (CTCs).

Read more
28 Apr 2020 12:28

UK TRADING UPDATE SUMMARY: Zenith Latest To Join Global Drive For PPE

UK TRADING UPDATE SUMMARY: Zenith Latest To Join Global Drive For PPE

Read more
28 Apr 2020 10:03

Angle works with skeleton R&D crew during lockdown

(Sharecast News) - Biopharmaceuticals group Angle said on Tuesday that progress had been impeded by the Covid-19 outbreak as the firm worked with a research and development skeleton crew in Guildford.

Read more
31 Mar 2020 12:21

UK TRADING UPDATE SUMMARY: Synairgen Starts Covid-19 Treatment Trial

UK TRADING UPDATE SUMMARY: Synairgen Starts Covid-19 Treatment Trial

Read more
31 Mar 2020 09:40

Angle UK, US, Canada operations 'severely disrupted' by Covid-19

(Sharecast News) - Liquid biopsy company Angle said on Tuesday that operations in the UK, US and Canada had all been "severely disrupted" by the Covid-19 pandemic.

Read more
3 Mar 2020 18:58

Angle Parsortix Test Used To Help Discover Brain Metastasis

Angle Parsortix Test Used To Help Discover Brain Metastasis

Read more
27 Feb 2020 14:09

Angle's Parsortix Beats Others In Assessing Kidney Cancer Patients

Angle's Parsortix Beats Others In Assessing Kidney Cancer Patients

Read more
27 Feb 2020 12:42

Angle upbeat on recent Parsortix research out of Italy

(Sharecast News) - Liquid biopsy company Angle announced on Thursday that Istituto Nazionale Tumori di Milano in Milan, Italy, has published results of work assessing the performance of its 'Parsortix' system in renal cell carcinoma (RCC), demonstrating key advantages of Parsortix.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.